RESUMEN
Objective To evaluate the efficacy and safety of carvedilol treatment for resistant renal parenchymal hypertension.Methods In this multi-center,open label,self-controlled trial,the enrolled resistant renal parenchymal hypertension patients stopped the use of ?-blocker and ?-blocker and took carvedilol 12.5 mg/d as initial dose and tittered to maximal dose of 50mg/d for 8 weeks.Other treatment was unchanged during the period.Results Among 183 patients enrolled,176 patients were followed up for 8 weeks.The systolic/diastolic BP decreased from(164.0?20.8)/(98.7?12.5)mm Hg to(140.0?14.2)/(84.5?24.7)mm Hg(both P
RESUMEN
About 10-15% of hypertension is secondary to renal disease. Cause of renal hypertension is renal parenchymal disease or renovascular problem. Hypertension in children which estimate at 1-2 % of all hypertension is very rare. We experienced a ease of renal parenchymal hypertension due to unilateral chronic reflux pyelonephritis in 10 year old boy, treated by nephrectomy.